Millions Affected As Nationwide Recall Issued For ADHD Medication

By Joe Lombardi From Daily Voice

A widely prescribed ADHD medication is being recalled nationwide after tests found it failed to dissolve properly in lab conditions.

The recall involves several lots of lisdexamfetamine dimesylate capsules — the generic form of Vyvanse — manufactured by Sun Pharmaceutical Industries. 

According to the Food and Drug Administration (FDA), the medication failed dissolution specifications during stability testing, meaning it did not break down as expected. 

That could reduce the drug’s effectiveness for patients who rely on consistent absorption for symptom control.

The FDA classified the action as a Class II recall, indicating a low risk of serious health effects but potential for temporary or reversible side effects.

The voluntary recall, initiated Friday, Oct. 28, covers multiple strengths ranging from 10 mg to 70 mg. 

The affected lots have expiration dates through 2026. Patients are urged to check prescription bottles for the listed lot numbers and contact their pharmacist or prescriber if affected.

Sun Pharmaceutical, which distributes the product from its facility in Cranbury, New Jersey, said it notified wholesalers and pharmacies nationwide by letter. The recall remains ongoing.

Lisdexamfetamine, a controlled substance and stimulant medication, is among the most prescribed ADHD treatments in the United States, with more than 9 million prescriptions issued in 2023.

Patients who believe they have the affected product should stop using it and arrange for a replacement or refund through their pharmacy or healthcare provider.